Emgality (galcanezumab-gnlm) — Highmark
episodic cluster headache
Initial criteria
- age ≥ 18 years
- diagnosis of episodic cluster headache (ICD-10: G44.01) with severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15–180 minutes when untreated
- attack frequency of at least one attack every other day during a cluster period
Reauthorization criteria
- reduction in mean weekly cluster headaches from baseline
- subsequent reauthorizations require sustained improvement